Alnylam Pharmaceuticals (ALNY) Operating Margin (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) reported Operating Margin of 23.02% for Q1 2026, down 3724.0% on a YoY basis from 0.64% in Q1 2025, and up 91.69% quarter-over-quarter from 12.01% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) Operating Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals has reported Operating Margin for 18 years, with the latest figure at 23.02% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin fell 3724.0% year-over-year to 23.02%; the trailing twelve-month figure through Mar 2026 stood at 17.54% (up 2401.0% YoY), and the FY2025 full-year result was 13.51%, up 2137.0% from the prior year.
- Operating Margin for Q1 2026 stood at 23.02%, up from 12.01% in the prior quarter.
- The five-year high for Operating Margin was 60.26% in Q1 2025, with the low at 97.63% in Q3 2022.
- Historically, Operating Margin has averaged 19.81% across 5 years, with a median of 15.35% in 2024.
- Annual changes were most pronounced in 2023 — Operating Margin jumped 12612 bps — and 2024, when it sank 4385 bps.
- Alnylam Pharmaceuticals' Operating Margin stood at 56.3% in 2022, then surged by 53 bps to 26.47% in 2023, then surged by 33 bps to 17.73% in 2024, then soared by 168 bps to 12.01% in 2025, then soared by 92 bps to 23.02% in 2026.
- The last three Operating Margin figures came in at 23.02% (Q1 2026), 12.01% (Q4 2025), and 29.46% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 23.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.02% |
| Dec 31, 2025 | 12.01% |
| Sep 30, 2025 | 29.46% |
| Jun 30, 2025 | -2.09% |
| Mar 31, 2025 | 60.26% |
| Dec 31, 2024 | -17.73% |
| Sep 30, 2024 | -15.35% |
| Jun 30, 2024 | 7.37% |
| Mar 31, 2024 | -8.79% |
| Dec 31, 2023 | -26.47% |
| Sep 30, 2023 | 28.50% |
| Jun 30, 2023 | -72.10% |
| Mar 31, 2023 | -46.92% |
| Dec 31, 2022 | -56.30% |
| Sep 30, 2022 | -97.63% |
| Jun 30, 2022 | -85.26% |
| Mar 31, 2022 | -68.80% |
| Dec 31, 2021 | -75.26% |
| Sep 30, 2021 | -96.83% |
| Jun 30, 2021 | -66.27% |